Varicella Vaccine (live) attenuated is a lyophilized preparation of the live, attenuated Oka strain of varicella-zoster virus (VZV). It is indicated for active immunization against varicella (chickenpox) in individuals 12 months of age and older. The vaccine induces both humoral and cell-mediated immunity, providing long-term protection. In India, it is a critical tool for preventing a highly contagious disease that can lead to serious complications, especially in adolescents, adults, and immunocompromised individuals.
Adult: 0.5 ml subcutaneously, two doses administered 4 to 8 weeks apart. For adults >13 years, a minimum interval of 4 weeks is recommended.
Note: Reconstitute the lyophilized vaccine ONLY with the supplied diluent. Administer immediately after reconstitution via subcutaneous injection, preferably in the outer aspect of the upper arm (deltoid region) or anterolateral thigh. Do not administer intravenously, intradermally, or intramuscularly. Use a separate, sterile syringe and needle for each individual.
The vaccine contains live varicella-zoster virus that has been attenuated (weakened) through serial passage in human and guinea pig cell cultures. Upon subcutaneous administration, it induces a subclinical, immunizing infection. This stimulates the production of varicella-specific antibodies (mainly IgG) and generates virus-specific memory B-cells and T-cells (both CD4+ and CD8+). This immune memory provides protection against subsequent wild-type VZV infection.
Pregnancy: CONTRANDICATED. Pregnancy should be avoided for 1 month following vaccination. No adverse outcomes have been reported from inadvertent administration, but theoretical risk of fetal infection exists. Part of routine pre-conception counseling.
Driving: No effect. However, vaccine-related fever or malaise may temporarily impair ability.
| Immunosuppressants (e.g., high-dose corticosteroids, cyclosporine, tacrolimus, chemotherapy) | Reduced immune response to vaccine; risk of disseminated vaccine virus infection. | Major |
| Salicylates (Aspirin) | Theoretical risk of Reye's syndrome following wild-type varicella. Avoid use for 6 weeks after vaccination as a precaution. | Moderate |
| Blood Products & Immunoglobulins (IVIG, VZIG) | May neutralize the vaccine virus, leading to vaccine failure. Defer vaccination for 3-11 months depending on product dose. | Major |
| Other Live Vaccines (e.g., MMR, Oral Polio, Yellow Fever) | If not given simultaneously, should be administered at least 4 weeks apart to avoid interference. | Moderate |